EWA
ALXN

Exencial Wealth Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Exencial Wealth Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,155
Closed -$213K – 150
2015
Q1 		$213K Hold
1,155
– – 0.09% 141
2014
Q4 		$213K Buy
+1,155
New +$214K 0.09% 141

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Exencial Wealth Advisors's ALXN Position: Q2 2015 in Review

Exencial Wealth Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 1,155 shares — an estimated $213K sold.

Exencial Wealth Advisors first reported a position in ALXN in Q4 2014 and held it in 2 quarters. The position peaked at $213K in Q1 2015. 547 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

  • Exencial Wealth Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Exencial Wealth Advisors sold 1,155 Alexion Pharmaceuticals shares in Q2 2015, an estimated $213K.
  • Exencial Wealth Advisors first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Exencial Wealth Advisors's Alexion Pharmaceuticals position peaked at $213K in Q1 2015.
  • 547 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Exencial Wealth Advisors's 13F filing for Q2 2015, filed 10 Aug 2015.